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The present study retrospectively examined the correlation between the outcome of patients with locally advanced oesophageal
squamous cell carcinoma (cT3-4 cN0-1 cM0) after multimodal treatment (radiochemotherapy7surgical resection), and the presence
of genetic polymorphisms in genes involved in folate metabolism. In total, 68 patients who took part in a prospective multicentric trial
received 5-fluorouracil (FU)-based radiochemotherapy, optionally followed by surgery. DNA was extracted from pretherapeutic
tumour biopsies and was subsequently genotyped for common genetic polymorphisms of three genes (MTHFR C677T, MTR
A2756G, TS tandem repeat polymorphism) involved in folate metabolism and potentially in sensitivity to 5-FU-based chemotherapy.
The genotypes were correlated with tumour response to polychemotherapy, radiochemotherapy and with overall survival. Tumours
with the MTR wild-type genotype (2756AA) showed a median survival time of 16 months, whereas tumours with an MTR variant
genotype (2756AG/2756GG) showed a median survival time of 42 months (P¼0.0463). No prognostic impact could be verified for
the genotypes of the MTHFR genes and the TS gene. Among tumours treated with radiochemotherapy and subsequent resection,
MTR variant genotype showed higher histopathological response rate than tumours with MTR wild-type genotype (P¼0.0442). In
contrast, no significant relationship between clinically determined tumour regression after polychemotherapy and polymorphisms of
the three genes under analysis was observed. In conclusion, pretherapeutic determination of the MTR A2756G polymorphism may
predict survival of multimodally treated oesophageal squamous cell carcinomas. Determination of MTHFR C677T and TS tandem
repeat polymorphism has no predictive value.
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In recent years, the prognosis of patients with oesophageal
squamous cell carcinoma has only slightly improved. The results
of surgical therapy have been poor, with 5-year survival rates
varying between 9 and 40%, even in resectable stages (Enzinger
and Mayer, 2003). Therefore, combined treatment modalities
including chemotherapy, irradiation and surgical treatment were
investigated in an increasing number of studies in order to
improve survival of oesophageal cancer patients. These studies
have indicated a complete response (CR) in 20–40% of patients
preoperatively treated with combined radiotherapy and chemo-
therapy (Forastiere et al, 1997). However, concerning survival,
proven benefit from combined neoadjuvant treatment modalities
has been unequivocally shown only for the subset of patients
showing a CR at histopathologic examination (Lerut et al, 1999;
Ancona et al, 2001; Bru ¨cher et al, 2004). It may, therefore, be of
great interest to find parameters that may help to identify those
patients who will benefit from multimodal treatment modalities
prior to the start of therapy (Forastiere et al, 1997; Lerut et al,
1999).
Methylenetetrahydrofolate reductase (MTHFR) and methionine
synthase (MTR) are key enzymes in folate metabolism. The
substrate for MTHFR, 5,10-methylene-tetrahydrofolate (THF) is
used for conversion of dUMP to dTMP by the enzyme thymidylate
synthase (TS). The enzyme product of MTHFR, 5-methyl-THF,
serves as carbon donor for the remethylation of homocysteine to
methionine, which is catalysed by the enzyme MTR (Figure 1)
(Choi et al, 1998; Balley and Gregory, 1999). The MTHFR gene is
highly polymorphic in the general population. The major
nucleotide 677 polymorphism (C to T) results in an alanine to
valine substitution, which alters enzyme activity (Goyette et al,
1994). Thus, individuals with the variant 677TT genotype have
about 30% of the in vitro MTHFR enzyme activity of those with the
677CC wild-type genotype, whereas heterozygotes (677CT) have
about 65% enzyme activity (Balley and Gregory, 1999). The
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sMethionine Synthase (MTR) gene contains a common polymor-
phism at bp 2756 (MTR A2756G), which causes an amino-acid
substitution from aspartic acid to glycine at codon 919 (D919G).
Individuals with the 2756GG genotype have lower plasma
homocysteine (or higher folate) levels than those with the
2756AA genotype (Tsai et al, 2000; Chen et al, 2001), indicating
an increased enzymatic activity of the variant genotype.
An accumulation of 5,10-methylene-THF resulting from the
MTHFR C677T polymorphism and/or the MTR A2756G poly-
morphism may have an effect on the response of cancer cells to
5-fluorouracil (5-FU), a chemotherapeutic agent frequently used in
the neoadjuvant treatment of oesophageal squamous cell carcino-
ma. This is because 5-FU can form a ternary complex involving
5-fluoro-20-deoyuridine-50-monophosphate (5-FdUMP), TS, and
5,10-methylene-THF. The formation of this complex inhibits TS
activity, which subsequently depletes intracellular thymidylate
levels and ultimately suppresses DNA synthesis. Therefore, the
MTHFR C677T polymorphism or the MTR A2756G polymorphism,
which increase the intracellular concentrations of 5,10-methylene-
THF, may increase the cytotoxic effect of 5-FU by increasing the
formation of the 5,10-methylene-THF-TS-5-FdUMP ternary com-
plex. The potential relevance of this mechanism has been recently
shown in vitro where in colon cancer cell lines the MTHFR 677T
polymorphism was associated with increased to sensitivity to 5-FU
treatment (Sohn et al, 2004). Moreover, patients with advanced
colorectal bearing the polymorphic MTHFR allele (either hetero-
zygous or homozygous) responded better to 5-FU-based chemo-
therapy than patients with the wild-type MTHFR allele (Cohen
et al, 2003). In contrast, the role of the MTHFR and MTR
polymorphisms in 5-FU-treated oesophageal cancer has not been
determined so far.
Additionally, the TS gene also contains a genetic polymorphism
that may be also involved in efficacy of 5-FU-based chemotherapy.
It is a 28-bp tandem repeat sequence within the 50-untranslated
region, and the vast majority of individuals show one of three
genotypes, that is, two tandem repeats (2R/2R), three tandem
repeats (3R/3R) or a heterozygous (2R/3R) genotype (Horie et al,
1995). This tandem repeat seems to function as an enhancer
element since in vitro studies have shown that stepwise increase of
TS mRNA expression and TS enzyme activity are associated with
increasing number of tandem repeat sequences. Indeed, there is
growing evidence that in colorectal cancer the TS 2R/2R genotype
is associated with improved response and survival following 5-FU-
based chemotherapy (Iacopetta et al, 2001; Villafranca et al, 2001;
DiPaolo and Chu, 2004).
Therefore, in the present study, genotypes of MTHFR, MTR and
TS were determined in preoperative biopsies derived from of
multimodally treated patients with locally advanced oesophageal
squamous cell carcinoma. Subsequently, these findings were
correlated with response to 5-FU-based chemotherapy and overall
survival.
MATERIAL AND METHODS
Patients
All patients of the present investigation were part of a prospective
multicentric phase III study and gave written, informed consent to
participate in this study. The results of this study, together with
the criteria for patient selection and study design, have been
extensively described elsewhere (Stahl et al, 1996, 2005).
Patient selection and study design
In total, 68 patients with locally advanced oesophageal cancer (i.e.
category T3/T4 according to the UICC classification (Sobin and
Wittekind, 1997) defined by CT scan and endoscopic ultrasound),
with or without regional lymph node metastases, were eligible.
Three courses of chemotherapy were administered within 9
weeks, followed by 4 weeks of radiotherapy with concomitant
chemotherapy during the first 7 days. After the administration of
chemotherapy and a cumulative dose of 40Gy of radiotherapy,
patients were either treated by at least further 25Gy of radio-
therapy (definitive radiochemotherapy) or by transthoracal
oesophageal resection. Postoperative treatment was not performed.
Preoperative chemotherapy and preoperative
radiochemotherapy
Chemotherapy consisted of folinic acid 300mgm
 2, etoposide
100mgm
 2, bolus 5-FU 500mgm
 2, and cisplatin 30mgm
 2 on
days 1–3, every 3 weeks (FLEP protocol).
Combined radiochemotherapy was administered on days 22–28
of the last course of chemotherapy. The oesophagus was irradiated
using parallel-opposed anterior and posterior fields and photons
from a 10- to 15-MV linear accelerator. A total dose of 40Gy was
given in daily fractions of 2Gy, five times per week. During the
first days of irradiation, the following chemotherapy was
administered: cisplatin 50mgm
 2 on days 2 and 8, and etoposide
100mgm
 2 on days 4–6.
Surgery
Resection of the oesophagus and the proximal stomach was
performed by a combined right thoracal and abdominal approach.
Resection included excision of the paraoesophageal, paracardial,
left gastric, and celiac lymph nodes.
Criteria for response to chemotherapy and
radiochemotherapy
Response to chemotherapy was evaluated clinically after the third
course and included barium oesophagogram, oesophagoscopy, and
computed tomography of the chest and abdomen. Response was
categorised as follows: CR – normal barium oesophagogram, no
visible tumour by oesophagoscopy, biopsies free of tumour tissue,
and normal CT; partial response (PR) – greater than 50% tumour
regression as evaluated by CT, and greater than 50% reduction of
intraoesophageal tumour extension as assessed by barium swallow
and oesophagoscopy; no change (NC) – less than 50% regression
of tumour extension, and no evidence of tumour progression;
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Figure 1 Schematic representation of the catalytic activity of the three
enzymes under investigation (Methionine Synthase, Thymidylate Synthase,
Methylenetetrahydrofolate Reductase (MTHFR)).
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sprogressive disease (PD) – increasing tumour obstruction
indicated by barium swallow or oesophagoscopy, and increasing
tumour diameter assessed by CT.
Response to radiochemotherapy was evaluated by histo-
pathological examination of cases that underwent transthoracal
oesophageal resection. In this evaluation, complete responders (no
viable tumour cells in the resection specimens) were separated
from cases were incomplete or no tumour regression was
detectable.
Pathologic review of pretherapeutic tumour biopsies
Tumour biopsies that had been endoscopically obtained during
pretherapeutic staging procedures were retrieved from the files of
pathologic institutes associated with the medical centers that took
part in this study. Of the 68 patients, 60 were male and eight were
female. The median age was 57 years (range: 37–70). A total of 58
tumours had been clinically categorised as T3 and 10 tumours had
been categorised as T4; 15 cases were in category N0 and 53 cases
were in category N1. Histologic slides of the biopsy specimens
were stained with hematoxylin and eosin for the determination of
tumour type and tumour grade according to the WHO criteria.
Three tumours were graded as G1, 34 tumours were graded as G2,
and 31 tumours were graded as G3.
Genotyping of MTHFR C677T, MTR A2756G and TS
For the determination of individual genotypes, genomic DNA
was extracted from formaldehyde-fixed tumour biopsies using
commercially available DNA-preparation kits (Qiagen, Hilden,
Germany). The MTHFR C677T genotype was determined by real-time
fluorescence PCR and melting curve analysis using a LightCycler
instrument (Roche Diagnostics, Mannheim, Germany). PCR
conditions, primers and probes and melting curve analysis were
applied as previously described (Sarbia et al, 2005). A melting
curve with a single peak at low melting temperature (501C)
indicates a homozygous variant (677TT) genotype, a single peak
at high melting temperature (601C) indicates a homozygous
wild-type (677CC) genotype, and a double peak indicates a
heterozygous genotype.
A PCR-RFLP assay was used to determine the MTR A2756G
genotype. The primers were forward 50-GAA CTA GAA GAC AGA
AAT TCT CTA-30 and reverse 50-CAT GGA AGA ATA TGA AGA
TAT TAG A-30 (Leclerc et al, 1996). The PCR product is digested
with HaeIII (New England Biolabs, Beverly, MA, USA); and the
amplified fragment of 189bp is cut into fragments of 159 and 30bp
in the presence of the G allele.
The promoter region of the TS gene was amplified by PCR using
the following primers: forward 50-AAAAGGCGCGCGGAAGGGG
TCCT-30 and reverse 50-TCCGAGCCGGCCACC AGGCAT-30
(Iacopetta et al, 2001). The PCR products were analysed by
length differences using ethidium-bromide-stained 2% agarose
gels.
Statistical analysis
SAS software package (SAS Institute Inc., Carey, NC, USA) was
used for statistical analyses. Statistical analysis of the correlation
between tumour regression following chemotherapy and genotypes
(MTHFR, MTR, TS) was performed by means of the two-tailed
Fisher’s exact test. Therefore, the parameters were dichotomised as
follows: tumour response (CR/PR vs NC/PD), MTHFR (CC vs CT/
TT), MTR (AA vs AG/GG) and TS (2R/2R vs 2R/3R/3R/3R). The
Kaplan–Meier method for analysis of censored data was used for
calculating survival rates and tested with the log-rank test and the
Wilcoxon test. Probabilities o0.05 were regarded as statistically
significant.
RESULTS
Correlation between genotypes and tumour regression
following chemotherapy and radiochemotherapy
Following FLEP chemotherapy, three patients (4.4%) received CR,
28 PR (41.2%), 32 NC (47.1%) and five PD (7.3%). Data on
histopathological response evaluation after radiochemotherapy was
available only in a subset of patients that underwent transthoracal
oesophageal resection (n¼20). Among these cases, seven (35.0%)
showed complete regression without viable residual tumour cells,
whereas in the other 13 (65.0%) cases either incomplete regression
or no histological signs of tumour regression were present.
In total, 67 samples could be genotyped successfully for the
MTHFR gene (98.5%), 64 for the MTR gene (94.1%) and 57 for the
TS gene (83.8%).
No significant relationship between tumour regression after
FLEP chemotherapy and polymorphisms of the three genes under
analysis was observed (Table 1). In contrast, response to radio-
chemotherapy was correlated with the MTR gene polymorphism.
Tumours with an MTR variant genotype (2756AG/2756GG)
showed complete histopathological regression in 46.2% of cases
whereas tumours with the MTR wild-type genotype (2756AA)
showed complete regression in 0% of cases (Table 2). (P¼0.0442
according to the w
2 test). No correlation between response to
radiochemotherapy and MTHFR and TS genotypes was found.
Survival analysis
The overall survival of all 68 patients has been followed up every 3
months for the first 3 years after the end of treatment; afterwards
every 6 months. One patient was lost to follow-up. At the end of
Table 1 Correlation between MTHFR, MTR and TS genotypes and
clinically determined tumour regression following polychemotherapy in
multimodally treated oesophageal SCC
a
Genotypes
Complete remission/
partial remission (%)
No change/
progression (%)
MTHFR 677CC 12 (46.2) 14 (53.8)
MTHFR 677CT/677TT 19 (46.3) 22 (53.7)
MTR 2756AA 20 (45.5) 24 (54.5)
MTR 2756AG/2756GG 9 (45.0) 11 (55.0)
TS 2R/2R 15 (45.5) 18 (54.5)
TS 2R/3R/3R/3R 12 (50.0) 12 (50.0)
aNo significant correlations according to w
2 test.
Table 2 Correlation between MTHFR, MTR and TS genotypes and
tumour regression as determined by histopathological examination
following radiochemotherapy in multimodally treated oesophageal SCC
Genotypes
Complete
histopathological
response (%)
Incomplete
histopathological
response/no
change/progression
(%) P-value
MTHFR 677CC 3 (33.3) 6 (66.7) NS
a
MTHFR 677CT/677TT 4 (40.0) 6 (60.0)
MTR 2756AA 0 (0) 6 (100) P¼0.0442
MTR 2756AG/
2756GG
6 (46.2) 7 (53.8)
TS 2R/2R 4 (40.0) 6 (60.0) NS
TS 2R/3R/3R/3R 2 (28.6) 5 (71.4)
aNo significant correlations according to w
2 test.
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sthe follow-up period (30.4.2005), 14 of the remaining 67 patients
(20.9%) were still alive. The follow-up time for all 67 patients
ranged from 4 to 114 months (median: 22 months). The follow-up
time for the 14 patients at risk ranged from 29 to 114 months
(median: 83 months).
All patients received complete treatment. Of the 67 patients
suitable for survival analyses, 38 received definitive radio-
chemotherapy and 29 were treated by radiochemotherapy and
subsequent oesophageal resection. Analysing all 67 patients,
tumours with the MTR wild-type genotype (2756AA) showed a
median survival time of 16 months whereas tumours with an MTR
variant genotype (2756AG/2756GG) showed a median survival
time of 42 months (Figure 2) (P¼0.0463 according to the
Wilcoxon test; P¼0.566 according to the log-rank test).
No prognostic impact could be verified for the genotypes of the
MTHFR genes and the TS gene either in the group as a whole
(Table 3) or when stratified, according to the type of therapy
(radiochemotherapy followed by resection or definitive radio-
chemotherapy).
DISCUSSION
The current study indicates that multimodally treated oesophageal
squamous cell carcinoma patients with the MTR 2756AG/2756GG
genotypes may have better survival than individuals with the MTR
2756AA genotype. Mechanistically, this may make sense taking
into account the putative effect of this polymorphism on folate
metabolism. Thus, MTR catalyses the transfer of the methyl base
from 5-methyl THF to homocysteine, thereby producing methio-
nine and THF. THF is the precursor of 50-formyl THF, which is an
inhibitor of thymidylate synthase in cooperation with 50-FdUMP,
which is a metabolite of 50-FU. Therefore, an increased activity of
the MTR gene may lead to an accumulation of 50-formyl THF and
thereby to a pronounced cytotoxic effect of 50-FU treatment. The
MTR 2756GG polymorphism was initially thought to be associated
with lower enzyme activity than the MTR 2756AA genotype
(Leclerc et al, 1996). However, more recent investigations indicate
that the variant genotypes (2756AG, 2756GG) may be associated
with lower homocysteine and/or higher methionine levels than the
wild-type genotype, implying a more effective enzyme activity
(Tsai et al, 2000; Chen et al, 2001; Silaste et al, 2001).
On the other hand, we did not observe any effect of the MTHFR
C677T polymorphism on survival. If the hypothesis is true that
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Figure 2 Survival curves of oesophageal SCC patients treated either by
neodjuvant radiochemotherapy and subsequent resection or by definitive
radiochemotherapy in relation Methionine Synthase genotype (n¼63, A).
Subgroup analysis for patients either treated by neoadjuvant radio-
chemotherapy and resection (n¼28, B) or by definitive radiochemo-
therapy (n¼35, C).
Table 3 Correlation between MTHFR, MTR and TS genotypes and overall survival in multimodally treated oesophageal SCC
Therapy Genotypes n Censored (%) Median survival (months) P-value
a
All patients MTHFR 677CC 25 4 (16%) 19 NS
b
MTHFR 677CT/677TT 41 10 (24%) 30
RCTx
c+resection MTHFR 677CC 13 1 (8%) 12 NS
MTHFR 677CT/677TT 15 4 (27%) 16
Definitive RCTx MTHFR 677CC 12 3 (25%) 55 NS
MTHFR 677CT/677TT 26 6 (23%) 30
All patients MTR 2756AA 43 7 (16%) 16 P¼0.0463
MTR 2756AG/2756GG 20 6 (30%) 42
RCTx+resection MTR 2756AA 23 3 (13%) 12 NS
MTR 2756AG/2756GG 5 1 (20%) 34
Definitive RCTx MTR 2756AA 20 4 (20%) 14 NS
MTR 2756AG/2756GG 15 5 (33%) 21
All patients TS 2R/2R 32 7 (22%) 17 NS
TS 2R/3R/3R/3R 24 5 (21%) 26
RCTx+resection TS 2R/2R 13 1 (8%) 9 NS
TS 2R/3R/3R/3R 10 3 (30%) 24
Definitive RCTx TS 2R/2R 19 6 (32%) 31 NS
TS 2R/3R/3R/3R 14 2 (14%) 26
aAccording to the Wilcoxon test.
bNot significant.
cRadiochemotherapy.
Genetic polymorphisms in oesophageal cancer
M Sarbia et al
206
British Journal of Cancer (2006) 94(2), 203–207 & 2006 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
saccumulation of 50-formyl THF increases the effect of 50-FU-based
therapy, this observation is difficult to understand. This is because
the variant genotype of the MTHFR gene is characterised by less
effective catalyzation of 50100-methylene THF to 50methyl THF and
thus to an accumulation of 50-formyl THF. However, one clearly
has to take into account that a large variety of other factors than
genetic polymorphisms may influence the activity of the key
enzymes involved in folate metabolism. Among others, enzyme
activities may be influenced by transcriptional regulation, post-
transcriptional modification and protein modification. Moreover,
5-FU was not the only cytotoxic drug used in the chemotherapy
protocol of the current study. Therefore, the putative effect of
5-FU-associated polymorphisms may be superposed by other
effects. Therefore, currently, only empirical studies like the present
one may clarify whether a given molecular aberration is associated
with clinically important effects or not. Nonetheless, determination
of genetic polymorphisms, for example, in peripheral blood, is
considered an attractive approach for response prediction because
this represents a relatively noninvasive approach for molecular
profiling. Other methods, for example, immunohistochemistry and
RT-PCR based on endoscopically obtained biopsies, always have
the inherent doubt of representativity for the entire tumour. On
the other hand, a recent study indicated that determination of
genetic polymorphisms in peripheral blood may not be represen-
tative for the situation in tumour tissue. Thus, Uchida et al (2004)
have shown that individuals heterozygous for the 28-bp poly-
morphism in the TS gene may have cancers that are homozygous
for this polymorphism due to loss of one allele during
carcinogenesis. Furthermore, they could show that the response
to 5-FU-based chemotherapy in these cases was comparable to
cases where the entire individual was homozygous. Therefore, it
may be superior to analyse the genotype of polymorphisms in
tumour cells than in peripheral blood.
In conclusion, our data indicate that determination of the
Methylenetetrahydrofolate Reductase C677T polymorphism and
the Thymidilate Synthase tandem repeat polymorphism does not
provide significant predictive information in multimodally treated
oesophageal squamous cell cancer patients. The potential effect of
the Methionine Synthase A2756G polymorphism deserves further
investigations in similar designed studies.
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